Toronto, Canada
ViroCarb Inc., a Canada-based biotechnology company founded in 2011, is pioneering a shift in antiviral drug development with its innovative drug platform. The company's mission is to tackle the clinical challenges posed by viral infections through a broad-spectrum antiviral solution, resonating with their slogan: "Antiviral company with a paradigm shift drug platform that provides broad-spectrum protection against pathogenic viruses."
The current antiviral landscape often focuses on a piecemeal approach, targeting a single virus at a time. In contrast, ViroCarb Inc. aims to create revolutionary small molecule solutions capable of blocking replication across a range of viruses, including Herpes, HIV, adenoviruses, and coronaviruses such as SARS-CoV2.
With the world confronting the reality of viral pandemics like COVID-19 and the associated risk of vaccine-resistant variants, ViroCarb Inc.'s groundbreaking approach could redefine antiviral treatment options. The strategic potential for investment is underscored by their last major backing from Creative Destruction Lab through a Non Equity Assistance investment in January 2021.
